Skip to main content
Equibles
IRWD logo

IRWD · Ironwood Pharmaceuticals Inc · Metrics

Track IRWD — free

Use IRWD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IRWD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.61 +0.05 (+1.40%)
Russell 2000 member Rebalance outlook locked
Market Cap
$588.25M
Shares
165.24M
Volume · Oct 20 1.64M Avg daily vol (3M) 1.99M

IRWD metrics

89 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.63
Market cap
$588.25M

Price action

20 metrics
Price change (1W)
-5.3%
Price change (30D)
-19.3%
Price change (3M)
-7.5%
Price change (6M)
-19.5%
Price change (YTD)
+5.6%
Price change (1Y)
+149.0%
Trailing year
Price change (5Y)
-73.5%
52-week high
$5.39
52-week low
$1.50
Change from 52-week high
-34.0%
Change from 52-week low
+137.3%
Annualized volatility
90.8%
Annualized volatility (3M)
60.0%
Beta
1.9
RSI (14D)
39.1
Price vs SMA 50
-12.8%
Price vs SMA 200
-11.5%
Avg volume (3M)
1.99M
Relative volume
0.8
Average dollar volume
$8.16M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
165.24M

Valuation

12 metrics
P / E (TTM)
4.6
Trailing earnings · reciprocal yield 21.6%
PEG ratio
0.0
EV / revenue
1.6×
reciprocal yield 61.1%
EV / EBITDA
—
EV / EBIT
2.7×
reciprocal yield 36.7%
P / sales
1.5×
reciprocal yield 67.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
21.9%
P / FCF
—
P / operating cash flow
3.1
reciprocal yield 32.1%
Earnings yield
22.5%

Historical valuation

8 metrics
P / E historical average (3Y)
31.8×
reciprocal yield 3.1%
P / E historical average (5Y)
17.9×
reciprocal yield 5.6%
EV / revenue historical average (3Y)
2.4×
reciprocal yield 41.5%
EV / revenue historical average (5Y)
2.9×
reciprocal yield 34.2%
EV / EBIT historical average (3Y)
4.8×
reciprocal yield 20.6%
EV / EBIT historical average (5Y)
5.7×
reciprocal yield 17.6%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
21.9%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
60.1%
Trailing 12 months
Net margin
33.4%
Gross profit (TTM)
$414.56M
Operating profit (TTM)
$234.17M
Net income (TTM)
$129.87M
Trailing 12 months
Diluted EPS (TTM)
$0.77
FCF margin
—
Effective tax rate
37.4%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
$0.40
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-1.61

Growth

11 metrics
Revenue growth YoY
+32.6%
Year over year
Net income growth YoY
+117.3%
Revenue (TTM)
$389.32M
Trailing 12 months
EPS growth YoY
+121.4%
Shares change YoY
-5.5%
Year over year · fewer shares
Revenue CAGR (3Y)
-10.3%
Revenue CAGR (5Y)
-5.3%
EPS CAGR (3Y)
-46.1%
EPS CAGR (5Y)
-25.6%
FCF CAGR (3Y)
-22.6%
FCF CAGR (5Y)
-5.3%

Quality

14 metrics
Return on equity
—
Return on assets
45.5%
Debt / equity
—
Current ratio
6.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
7.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$59.10M
Latest balance sheet
Cash & equivalents
$79.13M
Total assets
$285.13M
Total debt
$199.51M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$185.56M
Capital expenditures (TTM)
$35,000
R&D (TTM)
$88.69M
SG&A (TTM)
$64.55M
Stock compensation (TTM)
$14.32M
R&D / revenue
22.8%
Stock compensation / revenue
3.7%

Ownership (13F)

9 metrics
13F filers
212
13F filer change QoQ
-15
Institutional ownership
97.6%
Conviction holders (share of 13F filers)
0.5%
Crowding (high-turnover and private-fund holders)
36.4%
Private-fund adviser ownership
35.6%
Active holders' share change QoQ
-7.5%
Holder tenure
15.4
Price vs estimated holder cost
+11.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
20.8%

Short interest

3 metrics
Short interest
9.4%
Latest settlement · 6.2 days to cover
Days to cover
6.2d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1446847 CUSIP 46333X108 13F (30d) 18 filings 18 filers Visit website Investor relations